Half-year report · Q2
4570.TEDINET S100URML
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥444m | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥817m | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥366m | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥68m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥13m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥64m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥125m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥31m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥64m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥30m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥72m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥187m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥27m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥72m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥27m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥1.6bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥1.6bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥1.4bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥309m | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥353m | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.3bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥1.3bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.1bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥731m | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥734m | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥666m | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥675m | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥566m | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥562m | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥77m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥134m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥7m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥44m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥24m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥9m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥39m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥991,000 | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥3m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥7.68 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥20.05 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥2.88 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 81.2% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.1% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E00986-000Cosmeticsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3m |
| jpcrp040300-q2r_E00986-000Cosmeticsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3m |
| jpcrp040300-q2r_E00986-000Cosmeticsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥723,000 |
| jpcrp040300-q2r_E00986-000Immunity Relatedreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥441m |
| jpcrp040300-q2r_E00986-000Immunity Relatedreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥441m |
| jpcrp040300-q2r_E00986-000Immunity Relatedreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥67m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥444m |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥444m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥68m |
| jpcrp040300-q2r_E00986-000Cosmeticsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥2m |
| jpcrp040300-q2r_E00986-000Cosmeticsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2m |
| jpcrp040300-q2r_E00986-000Cosmeticsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥3m |
| jpcrp040300-q2r_E00986-000Immunity Relatedreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥363m |
| jpcrp040300-q2r_E00986-000Immunity Relatedreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥363m |
| jpcrp040300-q2r_E00986-000Immunity Relatedreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥16m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥366m |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥366m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥13m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 437
| Item | Context | Value | Unit |
|---|---|---|---|
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00986-000ImmunityRelatedReportableSegmentMember | 363410000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00986-000CosmeticsReportableSegmentsMember | 2106000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 365516000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration | 365516000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00986-000ImmunityRelatedReportableSegmentMember | 16379000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00986-000CosmeticsReportableSegmentsMember | -3079000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 13300000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1YTDDuration | 13300000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00986-000ImmunityRelatedReportableSegmentMember | 441150000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00986-000CosmeticsReportableSegmentsMember | 2977000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 444127000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 444127000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00986-000ImmunityRelatedReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00986-000CosmeticsReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00986-000ImmunityRelatedReportableSegmentMember | 441150000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00986-000CosmeticsReportableSegmentsMember | 2977000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 444127000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | CurrentYTDDuration | 444127000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00986-000ImmunityRelatedReportableSegmentMember | 67279000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00986-000CosmeticsReportableSegmentsMember | 723000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | 68002000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | CurrentYTDDuration | 68002000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-11-14 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第43期中(自 2024年４月１日 至 2024年９月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社免疫生物研究所 | |
| Company name in english cover page | FilingDateInstant | Immuno-Biological Laboratories Co.,Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 清藤 勉 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)群馬県藤岡市中字東田1091番地１ | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)0274-22-2889（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)常務取締役業務執行責任者兼事業グループ管理本部長 中川 正人 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)群馬県藤岡市中字東田1091番地１ | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)0274-22-2889（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)常務取締役業務執行責任者兼事業グループ管理本部長 中川 正人 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E00986 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45700 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社免疫生物研究所 | |
| Filer name in english | FilingDateInstant | Immuno-Biological Laboratories Co., Ltd. |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |